Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of previously untreated Chronic Lymphocytic Leukemia (CLL).~* Participant for whom the physician has decided to initiate CLL treatment with Venetoclax combo therapy with Obinutuzumab, according to approved local label up to 4 weeks (28 days) after Obinutuzumab treatment initiation.~Exclusion Criteria:~* Contraindications to Venclexta (Venetoclax) as listed on the approved local label in Russian Federation.~* Creatinine Clearance \< 30 milliLitres/minute.~* Richter syndrome or Transformation of CLL to aggressive non-Hodgkin lymphoma.~* Participating in a clinical trial with an investigative drug for CLL.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants Treated With Venetoclax + Obinutuzumab (Type: None): Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.

Based on this trial design, predict the completion outcome and termination type (if applicable).